keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer immunotherapy

keyword
https://www.readbyqxmd.com/read/29672601/expression-of-immune-checkpoint-regulators-cytotoxic-t-lymphocyte-antigen-4-ctla-4-and-programmed-death-ligand-1-pd-l1-in-female-breast-carcinomas
#1
Ari Kassardjian, Peter I Shintaku, Neda A Moatamed
BACKGROUND: Immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and the programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) have emerged as promising new targets for cancer therapeutics. While tumor expression of PD-L1 has been shown to have objective responses to anti-PD-L1 immunotherapies, the clinical implications of CTLA-4 expression in tumor cells or immune cells in the tumor microenvironment is still controversial. We investigated the expression of CTLA-4 and PD-L1 in human breast tumors and provided a scoring system for the systematic evaluation of CTLA-4 staining...
2018: PloS One
https://www.readbyqxmd.com/read/29669584/mri-based-response-patterns-during-neoadjuvant-chemotherapy-can-predict-pathological-complete-response-in-patients-with-breast-cancer
#2
Briete Goorts, Kelly M A Dreuning, Janneke B Houwers, Loes F S Kooreman, Evert-Jan G Boerma, Ritse M Mann, Marc B I Lobbes, Marjolein L Smidt
BACKGROUND: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability. METHODS: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included...
April 18, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29662533/highlights-from-the-10th-breast-gynaecological-and-immunotherapy-international-cancer-conference-bgicc-18-19-january-2018-cairo-egypt
#3
Hesham El-Ghazaly, Adel Aref, Nermeen Bahie-Eldin
During the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), which was held on 18 and 19 of January, 2018, in Cairo, Egypt, around 100 international, regional and national experts presented the latest updates in breast cancer, gynaecological cancers and immunotherapy in oncology. Through this report, we will try to highlight the important data and consensus issues that were discussed during the conference.
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29660759/parp-inhibitors-in-breast-cancer-bringing-synthetic-lethality-to-the-bedside
#4
REVIEW
Anita A Turk, Kari B Wisinski
Individuals with breast and ovarian cancer susceptibility gene 1 (BRCA1) or BRCA2 germline mutations have a significantly increased lifetime risk for breast and ovarian cancers. BRCA-mutant cancer cells have abnormal homologous recombination (HR) repair of DNA. In these tumors, the base excision repair (BER) pathway is important for cell survival. The poly(adenosine diphosphate-ribose) polymerase (PARP) enzymes play a key role in BER, and PARP inhibitors are effective in causing cell death in BRCA-mutant cells while sparing normal cells-a concept called synthetic lethality...
April 16, 2018: Cancer
https://www.readbyqxmd.com/read/29659677/targeting-the-human-epidermal-growth-factor-receptor-2-her2-oncogene-in-colorectal-cancer
#5
S Siena, A Sartore-Bianchi, S Marsoni, H I Hurwitz, S J McCall, F Penault-Llorca, S Srock, A Bardelli, L Trusolino
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic colorectal cancer (CRC) tumors are driven by amplification or mutation of HER2. MATERIALS AND METHODS: This paper reviews the role of HER2 as an oncogenic driver, a prognostic and predictive biomarker, and a clinically actionable target in CRC, considering the specifics of HER2 testing in this tumor type...
April 6, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29657904/immunotherapy-for-breast-cancer-current-and-future-strategies
#6
Austin D Williams, Kyle K Payne, Avery D Posey, Christine Hill, Jose Conejo-Garcia, Carl H June, Julia Tchou
Purpose of Review: The breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed researchers to harness the immune system with novel immunotherapy strategies, many of which have shown promise in breast cancer. This review discusses the application of immunotherapy to the treatment of breast cancer. Recent Findings: Both basic science and clinical trial data are rapidly developing in the use of immunotherapy for breast cancer...
December 2017: Current Surgery Reports
https://www.readbyqxmd.com/read/29644491/update-on-parp-inhibitors-in-breast-cancer
#7
REVIEW
Alexandra S Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung-Min Lee
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat certain ovarian cancers, including those with gBRCAm and olaparib for treatment of gBRCAm breast cancers. Several PARPi are now under clinical development for breast cancer in the various treatment settings. Recently, two phase III trials of olaparib (OlympiaD) and talazoparib (EMBRACA) demonstrated 3-month progression-free survival improvement with PARPi compared to physician's choice single agent chemotherapy in metastatic gBRCAm breast cancer...
April 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29644338/hypothesis-can-the-abscopal-effect-explain-the-impact-of-adjuvant-radiotherapy-on-breast-cancer-mortality
#8
REVIEW
Ismail Jatoi, John R Benson, Ian Kunkler
Radiotherapy is an integral component of loco-regional therapy for breast cancer. Randomized controlled trials indicate that increasing the extent of extirpative surgery primarily reduces the risk of local recurrences, while the addition of radiotherapy to surgery can also reduce the risk of distant recurrences, thereby lowering breast cancer-specific mortality. This may suggest an "abscopal" effect beyond the immediate zone of loco-regional irradiation that favorably perturbs the natural history of distant micrometastases...
2018: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29622581/targeting-tissue-factor-for-immunotherapy-of-triple-negative-breast-cancer-using-a-second-generation-icon
#9
Zhiwei Hu, Rulong Shen, Amanda Campbell, Elizabeth L McMichael, Lianbo Yu, Bhuvaneswari Ramaswamy, Cheryl A London, Tian Xu, William E Carson
Triple-negative breast cancer (TNBC) is a leading cause of breast cancer death and is often associated with BRCA1 and BRCA2 mutation. Due to the lack of validated target molecules, no targeted therapy for TNBC is approved. Tissue factor (TF) is a common yet specific surface target receptor for cancer cells, tumor vascular endothelial cells and cancer stem cells in several types of solid cancers including breast cancer. Here we report evidence supporting the idea that TF is a surface target in TNBC. We used in vitro cancer lines and in vivo tumor xenografts in mice, all with BRCA1 or BRCA2 mutations, derived from patients' tumors...
April 5, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29622464/a-comprehensive-pan-cancer-molecular-study-of-gynecologic-and-breast-cancers
#10
Ashton C Berger, Anil Korkut, Rupa S Kanchi, Apurva M Hegde, Walter Lenoir, Wenbin Liu, Yuexin Liu, Huihui Fan, Hui Shen, Visweswaran Ravikumar, Arvind Rao, Andre Schultz, Xubin Li, Pavel Sumazin, Cecilia Williams, Pieter Mestdagh, Preethi H Gunaratne, Christina Yau, Reanne Bowlby, A Gordon Robertson, Daniel G Tiezzi, Chen Wang, Andrew D Cherniack, Andrew K Godwin, Nicole M Kuderer, Janet S Rader, Rosemary E Zuna, Anil K Sood, Alexander J Lazar, Akinyemi I Ojesina, Clement Adebamowo, Sally N Adebamowo, Keith A Baggerly, Ting-Wen Chen, Hua-Sheng Chiu, Steve Lefever, Liang Liu, Karen MacKenzie, Sandra Orsulic, Jason Roszik, Carl Simon Shelley, Qianqian Song, Christopher P Vellano, Nicolas Wentzensen, John N Weinstein, Gordon B Mills, Douglas A Levine, Rehan Akbani
We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of four gynecological types plus breast. Our aims were to identify shared and unique molecular features, clinically significant subtypes, and potential therapeutic targets. We found 61 somatic copy-number alterations (SCNAs) and 46 significantly mutated genes (SMGs). Eleven SCNAs and 11 SMGs had not been identified in previous TCGA studies of the individual tumor types. We found functionally significant estrogen receptor-regulated long non-coding RNAs (lncRNAs) and gene/lncRNA interaction networks...
April 1, 2018: Cancer Cell
https://www.readbyqxmd.com/read/29617184/targeting-interleukin-22-for-cancer-therapy
#11
Anamarija Markota, Stefan Endres, Sebastian Kobold
Interleukin-22 (IL-22) is a member of IL-10 family of cytokines. IL-22 induces proliferative and anti-apoptotic signaling pathways and production of anti-microbial molecules that enhance tissue regeneration and host defense. IL-22 has also been identified as a cancer-promoting cytokine since deregulation of the IL-22-IL-22R1 system is linked to different cancer entities including lung, breast, gastric, pancreatic and colon cancers. T cells and innate lymphoid cells are the main cellular sources of IL-22. Expression of its specific receptor IL-22R1 is restricted to the non-hematopoietic cells which makes the IL-22-IL-22R1 pathway an attractive target for anti-cancer therapy...
April 4, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29615613/multi-omics-analysis-reveals-neoantigen-independent-immune-cell-infiltration-in-copy-number-driven-cancers
#12
Daniel J McGrail, Lorenzo Federico, Yongsheng Li, Hui Dai, Yiling Lu, Gordon B Mills, Song Yi, Shiaw-Yih Lin, Nidhi Sahni
To realize the full potential of immunotherapy, it is critical to understand the drivers of tumor infiltration by immune cells. Previous studies have linked immune infiltration with tumor neoantigen levels, but the broad applicability of this concept remains unknown. Here, we find that while this observation is true across cancers characterized by recurrent mutations, it does not hold for cancers driven by recurrent copy number alterations, such as breast and pancreatic tumors. To understand immune invasion in these cancers, we developed an integrative multi-omics framework, identifying the DNA damage response protein ATM as a driver of cytokine production leading to increased immune infiltration...
April 3, 2018: Nature Communications
https://www.readbyqxmd.com/read/29615400/neth2pan-a-computational-tool-to-guide-mhc-peptide-prediction-on-murine-tumors
#13
Christa I DeVette, Massimo Andreatta, Wilfried Bardet, Steven J Cate, Vanessa I Jurtz, Kenneth W Jackson, Alana L Welm, Morten Nielsen, William H Hildebrand
With the advancement of personalized cancer immunotherapies, new tools are needed to identify tumor antigens and evaluate T-cell responses in model systems, specifically those that exhibit clinically relevant tumor progression. Key transgenic mouse models of breast cancer are generated and maintained on the FVB genetic background, and one such model is the mouse mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT) mouse - an immunocompetent transgenic mouse that exhibits spontaneous mammary tumor development and metastasis with high penetrance...
April 3, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29601471/nanopulse-stimulation-nps-induces-tumor-ablation-and-immunity-in-orthotopic-4t1-mouse-breast-cancer-a-review
#14
REVIEW
Stephen J Beebe, Brittany P Lassiter, Siqi Guo
Nanopulse Stimulation (NPS) eliminates mouse and rat tumor types in several different animal models. NPS induces protective, vaccine-like effects after ablation of orthotopic rat N1-S1 hepatocellular carcinoma. Here we review some general concepts of NPS in the context of studies with mouse metastatic 4T1 mammary cancer showing that the postablation, vaccine-like effect is initiated by dynamic, multilayered immune mechanisms. NPS eliminates primary 4T1 tumors by inducing immunogenic, caspase-independent programmed cell death (PCD)...
March 30, 2018: Cancers
https://www.readbyqxmd.com/read/29572968/implantable-synthetic-immune-niche-for-spatiotemporal-modulation-of-tumor-derived-immunosuppression-and-systemic-antitumor-immunity-postoperative-immunotherapy
#15
Hathaichanok Phuengkham, Chanyoung Song, Soong Ho Um, Yong Taik Lim
The development of biomaterial-based immune niches that can modulate immunosuppressive factors in tumor microenvironment (TME) will be a key technology for improving current cancer immunotherapy. Here, implantable, engineered 3D porous scaffolds are designed to generate synergistic action between myeloid-derived suppressor cell (MDSC)-depleting agents, which can accommodate the establishment of a permissive immunogenic microenvironment to counteract tumor-induced immunosuppression, and cancer vaccines consisting of whole tumor lysates and nanogel-based adjuvants, which can generate tumor antigen-specific T cell responses...
March 23, 2018: Advanced Materials
https://www.readbyqxmd.com/read/29556312/plac1-specific-tcr-engineered-t-cells-mediate-antigen-specific-antitumor-effects-in-breast-cancer
#16
Qiongshu Li, Muyun Liu, Man Wu, Xin Zhou, Shaobin Wang, Yuan Hu, Youfu Wang, Yixin He, Xiaoping Zeng, Junhui Chen, Qubo Liu, Dong Xiao, Xiang Hu, Weibin Liu
Placenta-specific 1 (PLAC1), a novel cancer-testis antigen (CTA), is expressed in a number of different human malignancies. It is frequently produced in breast cancer, serving a function in tumorigenesis. Adoptive immunotherapy using T cell receptor (TCR)-engineered T cells against CTA mediates objective tumor regression; however, to the best of our knowledge, targeting PLAC1 using engineered T cells has not yet been attempted. In the present study, the cDNAs encoding TCRα- and β-chains specific for human leukocyte antigen (HLA)-A*0201-restricted PLAC1 were cloned from a cytotoxic T-lymphocyte, generated by in vitro by the stimulation of CD8+ T cells using autologous HLA-A2+ dendritic cells loaded with a PLAC1-specific peptide (p28-36, VLCSIDWFM)...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29550074/phase-i-study-of-intrapleural-gene-mediated-cytotoxic-immunotherapy-in-patients-with-malignant-pleural-effusion
#17
Charu Aggarwal, Andrew R Haas, Susan Metzger, Laura K Aguilar, Estuardo Aguilar-Cordova, Andrea G Manzanera, Gregoria Gómez-Hernández, Sharyn I Katz, Evan W Alley, Tracey L Evans, Joshua M Bauml, Roger B Cohen, Corey J Langer, Steven M Albelda, Daniel H Sterman
Gene-mediated cytotoxic immunotherapy (GMCI) is an immune strategy implemented through local delivery of an adenovirus-based vector expressing the thymidine kinase gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug valacyclovir. A phase I dose escalation trial of GMCI followed by chemotherapy was conducted in patients with malignant pleural effusion (MPE). AdV-tk was administered intrapleurally (IP) in three cohorts at a dose of 1 × 1012 to 1013 vector particles. Primary endpoint was safety; secondary endpoints included response rate, progression-free survival, and overall survival...
February 21, 2018: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/29549047/the-breast-cancer-antigen-5t4-interacts-with-rab11-and-is-a-target-and-regulator-of-rab11-mediated-trafficking
#18
Janelle L Harris, Keyur Dave, Jeffrey Gorman, Kum Kum Khanna
BACKGROUND AND AIMS: 5T4 is a transmembrane glycoprotein with limited expression in normal adult tissues and expression in some solid tumours. It is unclear whether 5T4 is preferentially expressed by stem or differentiated cell types. Modes of 5T4 regulation are unknown despite its ongoing development as a cancer immunotherapy target. Our aims were to clarify the differentiation status of 5T4 expressing cells in breast cancer and to understand the mechanism underlying 5T4 membrane presentation...
March 13, 2018: International Journal of Biochemistry & Cell Biology
https://www.readbyqxmd.com/read/29536332/comparative-analysis-of-the-effect-of-different-radiotherapy-regimes-on-lymphocyte-and-its-subpopulations-in-breast-cancer-patients
#19
C Yuan, Q Wang
PURPOSE: The aim of this study was to determine whether different radiotherapy (RT) fractionation schemes induce disparate effects on lymphocyte and its subsets in breast cancer patients. METHODS: 60 female patients diagnosed with breast cancer were recruited in this study after receiving modified radical mastectomy and were randomly divided into two groups. One group received irradiation at a standard dose of 50 Gy in 25 fractions and the other at a dose of 40...
March 13, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29523766/nucleoside-diphosphate-kinase-3-nme3-enhances-tlr5-induced-nf-%C3%AE%C2%BAb-activation
#20
Kelly Flentie, Caleb Gonzalez, Brandon Kocher, Yue Wang, Hongtu Zhu, Jayne Marasa, David Piwnica-Worms
Bacterial flagellin is a potent activator of NF-κB signaling, inflammation and host innate immunity, and recent data indicate that flagellin represents a novel anti-tumor ligand acting through toll-like receptor 5 (TLR5) and the NF-κB pathway to induce host immunity and aid in the clearance of tumor xenografts. To identify innate signaling components of TLR5 responsible for these anti-tumor effects, a loss-of-function high-throughput screen was employed utilizing carcinoma cells expressing a dynamic NF-κB bioluminescent reporter stimulated by Salmonella typhimurium expressing flagellin...
March 9, 2018: Molecular Cancer Research: MCR
keyword
keyword
25007
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"